Phase II trial of gaboxadol [OV101] in patients with fragile X syndrome
Phase of Trial: Phase II
Latest Information Update: 15 Mar 2018
At a glance
- Drugs Gaboxadol - Ovid Therapeuticsgaboxadol (Primary)
- Indications Fragile X syndrome
- Focus Therapeutic Use
- 15 Mar 2018 According to an Ovid Therapeutics media release, the company intends to initiate this trial in 2018.
- 04 Jun 2015 Planned initiation date changed from 1 Jun 2015 to 1 Jan 2016 according to an Ovid Therapeutics media release.
- 20 Apr 2015 New trial record